UNIVERSITY OF WASHINGTON
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1861-01-01
- Employees
- 10K
- Market Cap
- -
Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya
Phase 3
Terminated
- Conditions
- HIV Infections
- Interventions
- Drug: AZT/3TC/NVP (zidovudine/lamivudine/nevirapine)Drug: AZT/3TC/ABC (zidovudine/lamivudine/abacavir)Drug: d4T/3TC/NVP (stavudine/lamivudine/nevirapine)Drug: d4T/3TC/ABC (stavudine/lamivudine/abacavir)Drug: ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir)Drug: ABC/3TC/NVP (abacavir/lamivudine/nevirapine)
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 34
- Registration Number
- NCT00427297
- Locations
- 🇰🇪
Kenyatta National Hospital, University of Nairobi, Nairobi, Kenya
Optimizing Pediatric HIV-1 Treatment, Nairobi, Kenya
Not Applicable
Terminated
- Conditions
- HIV Infections
- Interventions
- Drug: HAART
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 140
- Registration Number
- NCT00428116
ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
Phase 1
Completed
- Conditions
- Stage IIIC Breast CancerStage IV Breast CancerMale Breast CancerRecurrent Breast CancerStage IIIA Breast CancerStage IIIB Breast Cancer
- Interventions
- Biological: ONTAKOther: flow cytometryOther: immunohistochemistry staining methodOther: enzyme-linked immunosorbent assayOther: laboratory biomarker analysisGenetic: protein expression analysis
- First Posted Date
- 2007-01-23
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 15
- Registration Number
- NCT00425672
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Lung Cancer
- First Posted Date
- 2007-01-23
- Last Posted Date
- 2013-05-06
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 50
- Registration Number
- NCT00425646
- Locations
- 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer
Phase 2
Completed
- Conditions
- Musculoskeletal ComplicationsRecurrent Breast CancerStage II Breast CancerArthralgiaPainStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerStage I Breast Cancer
- Interventions
- Dietary Supplement: calcium carbonateOther: laboratory biomarker analysisDietary Supplement: calcium citrateDietary Supplement: calcium glucarateDietary Supplement: cholecalciferolProcedure: assessment of therapy complicationsProcedure: musculoskeletal complications management/prevention
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 100
- Registration Number
- NCT00416715
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Phase 2
Completed
- Conditions
- Stage III Squamous Cell Carcinoma of the NasopharynxStage III Squamous Cell Carcinoma of the OropharynxStage III Squamous Cell Carcinoma of the HypopharynxStage IV Squamous Cell Carcinoma of the HypopharynxStage III Squamous Cell Carcinoma of the LarynxStage III Squamous Cell Carcinoma of the Lip and Oral CavityStage IV Squamous Cell Carcinoma of the LarynxStage IV Squamous Cell Carcinoma of the Lip and Oral CavityStage IV Squamous Cell Carcinoma of the NasopharynxStage IV Squamous Cell Carcinoma of the Oropharynx
- Interventions
- Radiation: 3-dimensional conformal radiation therapyRadiation: intensity-modulated radiation therapyProcedure: quality-of-life assessment
- First Posted Date
- 2006-12-13
- Last Posted Date
- 2013-05-10
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 204
- Registration Number
- NCT00410826
- Locations
- 🇺🇸
Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
🇺🇸University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
🇺🇸University of New Mexico Health Science CCOP, Albuquerque, New Mexico, United States
Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Stage IIIB Non-small Cell Lung CancerRecurrent Non-small Cell Lung CancerMalignant Pleural EffusionStage IV Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2006-12-07
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 34
- Registration Number
- NCT00408460
- Locations
- 🇺🇸
University of New Mexico Cancer Center, Albuquerque, New Mexico, United States
🇺🇸Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery
Phase 2
Completed
- Conditions
- Stage IA Breast CancerStage II Breast CancerStage IIIC Breast CancerStage IB Breast CancerStage IIIA Breast CancerHER2-positive Breast CancerStage IV Breast CancerEstrogen Receptor-positive Breast CancerStage IIIB Breast Cancer
- Interventions
- Biological: filgrastimBiological: trastuzumabOther: laboratory biomarker analysisProcedure: quality-of-life assessment
- First Posted Date
- 2006-12-05
- Last Posted Date
- 2017-08-31
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 60
- Registration Number
- NCT00407888
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Pedestrian Behavior Following Implementation of a Walking School Bus
Not Applicable
Completed
- Conditions
- Obesity
- Interventions
- Behavioral: Walking School Bus Program
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 735
- Registration Number
- NCT00402701
- Locations
- 🇺🇸
Harborview Injury Prevention Research Center - University of Washington, Seattle, Washington, United States
Oral Androgens in Man-4: (Short Title: Oral T-4)
Phase 1
Completed
- Conditions
- Contraception
- Interventions
- First Posted Date
- 2006-11-14
- Last Posted Date
- 2008-09-22
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 20
- Registration Number
- NCT00399165
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States